Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

We aimed to determine the maximum-tolerated dose (MTD) clinical toxicities, pharmacokinetics, and pharmacodynamics of oral JM216 given once daily for 5 days to cancer patients. Patients who fulfilled standard phase I trial criteria were enrolled. Oral JM216 was given at doses based on patient body-s...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 15; číslo 7; s. 2691
Hlavní autoři:	McKeage, M J, Raynaud, F, Ward, J, Berry, C, O'Dell, D, Kelland, L R, Murrer, B, Santabárabara, P, Harrap, K R, Judson, I R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.07.1997
Témata:	Administration, Oral Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Area Under Curve Drug Administration Schedule Female Gastrointestinal Diseases - chemically induced Hematologic Diseases - chemically induced Humans Male Middle Aged Neoplasms - blood Neoplasms - drug therapy Organoplatinum Compounds Severity of Illness Index Ultrafiltration
ISSN:	0732-183X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!